Immune-complex-membranoproliferative glomerulonephritis

Clinical trials for Immune-complex-membranoproliferative glomerulonephritis explained in plain language.

Never miss a new study

Get alerted when new Immune-complex-membranoproliferative glomerulonephritis trials appear

Sign up with your email to follow new studies for Immune-complex-membranoproliferative glomerulonephritis, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Trials to join now! 1

New hope for rare kidney patients: Long-Term drug trial shows promise

Disease control Recruiting now

This study looks at the long-term safety and effectiveness of a drug called iptacopan for people with two rare kidney diseases: C3 glomerulopathy and IC-MPGN. About 225 adults who have already completed a previous iptacopan study will take the drug for an extended period. The goa…

Matched conditions: IMMUNE-COMPLEX-MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS

Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control

Last updated Aug 09, 2026 00:00 UTC

Immune-complex-membranoproliferative glomerulonephritis

Get alerted when new Immune-complex-membranoproliferative glomerulonephritis trials appear

New hope for rare kidney patients: Long-Term drug trial shows promise